Stepmarch Pharmaceutical announced that its controlling subsidiary Stepmarch (Guangzhou) Medical Diagnosis will transfer 60% equity of Hunan Zhongce held by it to board member Yang Futai for 1 yuan. After the transfer, Stepmarch (Guangzhou) will no longer hold any equity. As of 2025, Hunan Zhongce has assets of 3,449,000 yuan, liabilities of 7,952,000 yuan, net assets of -4,503,000 yuan, operating revenue of 10,757,000 yuan, and net loss of -10,241,000 yuan.